Back
#1
32.1%
Top 0.3%
19.9%
Top 50%
13.3%
Top 59%
4.7%
Top 36%
4.3%
Top 10%
1.7%
Top 0.4%
1.7%
Top 12%
1.3%
Top 35%
1.3%
Top 22%
0.8%
Top 19%
0.8%
Top 18%
0.8%
Top 63%
0.6%
Top 36%
0.5%
Top 25%
0.5%
Top 19%
0.5%
Real-world utilization and initial experience with aflibercept-ayyh (PAVBLU(R)) for retinal disorders in United States retina practices: A descriptive retrospective analysis
2026-02-27
ophthalmology
Title + abstract only
View on medRxiv
Show abstract
IntroductionAnti-vascular endothelial growth factor (anti-VEGF) therapies are standards of care for vision-threatening retinal diseases. This retrospective observational study describes demographics, utilization, best recorded visual acuity (BRVA), and safety among eyes with neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR), diabetic macular edema (DME), or retinal vein occlusion (RVO) treated with the biosimilar aflibercept-ayyh (PAVBLU(R)) in routine clinical pract...
Predicted journal destinations
1
Ophthalmology Science
15 training papers
2
Translational Vision Science & Technology
18 training papers
3
PLOS ONE
1737 training papers
4
Scientific Reports
701 training papers
5
BMJ Open
553 training papers
6
Journal of Clinical Medicine
77 training papers
7
F1000Research
28 training papers
8
Cureus
64 training papers
9
eLife
262 training papers
10
Frontiers in Medicine
99 training papers
11
npj Digital Medicine
85 training papers
12
PLOS Digital Health
88 training papers
13
Nature Communications
483 training papers
14
JAMA Network Open
125 training papers
15
Journal of Medical Internet Research
81 training papers
16
Vaccines
131 training papers